This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension
by Zacks Equity Research
Amgen's (AMGN) leukemia drug, Blincyto receives positive CHMP opinion for label expansion to include minimal residual disease.
Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs
by Zacks Equity Research
Per a Wall Street report, Pfizer (PFE) plans to increase the list prices of its 41 prescription drugs in 2019.
The Zacks Analyst Blog Highlights: Pfizer, Cisco, Southern, SunTrust Banks and AmerisourceBergen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Cisco, Southern, SunTrust Banks and AmerisourceBergen
uniQure Up on Positive Data From Mid-Stage Hemophilia Study
by Zacks Equity Research
uniQure's (QURE) gene therapy candidate, AMT-061, demonstrates significant improvement in hemophilia B patients in a mid-stage study. Investors' sentiment improves.
Top Research Reports for Pfizer, Cisco & Southern Company
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Cisco (CSCO) and Southern Company (SO).
Lilly Offers Updates on Progress of Headache Disorder Drugs
by Zacks Equity Research
Eli Lilly (LLY) files NDA with FDA for migraine candidate, lasmiditan. FDA grants Breakthrough Therapy status to Emgality for episodic cluster headache indication.
Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes
by Zacks Equity Research
Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.
Shire's Filing Accepted by FDA for Gattex's Label Expansion
by Zacks Equity Research
The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.
Pfizer (PFE) Stock Moves -0.38%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.11, marking a -0.38% move from the previous day.
Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
by Zacks Equity Research
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction
by Zacks Equity Research
Aerie's (AERI) Q3 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.
Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $42.99, moving -1.22% from the previous trading session.
Can Low Volatility ETFs Protect Your Portfolio?
by Neena Mishra
Low volatility ETFs are designed to perform well in a volatile market environment, here is what investors need to know.
Beaten-Down Pharma ETFs to Buy Post Q3 Results
by Sweta Killa
Despite strong results, the broad market sell-off took the sheen from the pharma ETFs over the past month. These funds have a Zacks ETF Rank #2 (Buy), suggesting solid entry point on beaten down prices.
Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates
by Zacks Equity Research
Corcept (CORT) reports in-line earnings in the third quarter of 2018 and reaffirms its revenue guidance for 2018.
Exelixis (EXEL) Q3 Earnings, Revenues Beat on Cabometyx Sales
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenue beat expectations in the third-quarter propelled by strong sales of Cabometyx.
Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates
by Zacks Equity Research
Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
by Zacks Equity Research
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
by Zacks Equity Research
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Dow 30 Stock Roundup: Apple, Coca-Cola, DowDuPont Earnings Impress
by Swarup Gupta
The index experienced one of its better weeks in recent times, buoyed by strong earnings and hopes of a resolution to trade tensions.
Pfizer and Coca-Cola Earnings Help Safer Income Stocks Shine
by Ryan McQueeney
After a volatile October, Ryan McQueeney highlights two income companies that fared better than the broader markets during the selloff---Pfizer and Coca-Cola---and explains why earnings and defensive posturing might have helped the stocks.
PFE vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?